Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.
Sunitinib is a targeted cancer medicine, a multi-kinase inhibitor that blocks VEGF and PDGF receptors and KIT, among others, cutting off tumour blood vessel growth and growth signals. It is used for advanced kidney cancer, gastrointestinal stromal tumours (GIST) after imatinib, and neuroendocrine tumours of the pancreas. It is sold as Sutent.
Sunitinib is broken down by CYP3A4 into an active form and pumped out of cells by ABCB1 and ABCG2. Studies have linked variants in these genes and in CYP3A5 to drug levels and side effects such as high blood pressure, fatigue and hand-foot syndrome, and VEGF pathway genes (VEGFA, KDR, FLT4) to response. The findings come from single or a few studies, and there is no CPIC or DPWG guideline.
Every published finding on gene variants and Sunitinib. Upload your DNA file to see which of these rows apply to you.
PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.
FLT3 rs1933437: Level 3. Toxicity: Leukopenia, Myelosuppression, Neutropenia, Thrombocytopenia. 4.
ABCG2 rs2231142: Level 3. Toxicity: Neoplasms. 3.
ABCB1 rs1045642: Level 3. Toxicity: Renal Cell Carcinoma. 3.
CYP3A5 rs776746: Level 3. Dosage, Toxicity: Renal Cell Carcinoma. 2.
Studies of how quickly the body processes this medication.
Studies of how well it worked in people carrying a variant.
Studies of how much of the drug people needed or tolerated.
Studies of side effects in people carrying a variant.
Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.
More drugs from the same category
Apatinib (Tyrosine Kinase Inhibitors)
Gilotrif (Tyrosine Kinase Inhibitors)
Gleevec (Tyrosine Kinase Inhibitors)
Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.
Content updated September 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com